The US FDA rejected a request to use MDMA for PTSD treatment, asking for an additional Phase 3 trial due to inadequate evidence for approval.
Drugmaker Lykos plans to meet with the FDA for reconsideration, citing disappointment for patients with PTSD who lack new treatment options for over two decades.
Combat veterans advocate for MDMA-assisted therapy as hope for PTSD treatment, with bipartisan support from members of Congress urging FDA's approval.
Collection
[
|
...
]